Moderna Wins Permission to Submit Coronavirus Vaccine Candidate for Fast-Track Approval in Europe

Fresh off its announcement that it has submitted its coronavirus vaccine candidate for regulatory approval in Canada, Moderna (NASDAQ: MRNA) said Wednesday it is in a similar situation in Europe. The company announced that the European Medicines Agency (EMA) has formally notified it that mRNA-1273 is eligible for submission of an application for fast-track approval.

If granted European Union Marketing Authorization, Moderna would be able to distribute the approved vaccine throughout the 27-country economic bloc that includes such nations as Germany and Spain.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

"We are pleased with the productive interactions with the European regulatory authorities at the National level and at the EMA level to date and we appreciate their valuable guidance and confidence in Moderna to pursue an MAA submission for approval in Europe for our COVID-19 vaccine candidate," the biotech quoted its CEO Stephane Bancel as saying.

"European partners, investors, and citizens have been part of Moderna from the beginning of the company and have played an important role in Moderna's progress," he added.

The company is already poised to manufacture the vaccine in Europe, should it be approved. It has contracted with Spain-based ROVI and Switzerland's Lonza to manufacture and fill-finish mRNA-1273.

The vaccine candidate is currently in the midst of Phase 3 trials, making it one of only a handful of potential vaccines in such a late stage of testing. That, plus the fact that it has shown to be very efficacious in early stage testing, puts it high on the leaderboard for relatively early approval throughout the world.

In spite of all that, Moderna's stock fell in Wednesday trading. It closed down by 2.2%, compared to only a 0.7% slide for the S&P 500 index.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More